A Phase 1/2 interventional study of Caspofungin Acetate 50 MG and Physiologic saline in Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection and Pneumocystis Infections, sponsored by University Hospital, Tours. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by University Hospital, Tours · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Pneumonia, Pneumocystis with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Pneumonia, Pneumocystis · France.
Among the 15 studies in Pneumonia, Pneumocystis with a site in France, this one is one of 2 that started in 2025, is the only one in phase 1/2, and was the 12th registered.
108 studies on the registry are indexed under Pneumonia, Pneumocystis; 16 are open to participants now.
Browse Pneumonia, Pneumocystis studies →3 of the 15 studies in Pneumonia, Pneumocystis with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 9 Pneumonia, Pneumocystis studies recruiting now, 6 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2
First in 2010; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 231 across 56 interventional studies indexed under Pneumonia, Pneumocystis.
Median enrollment 222 across the 7 interventional studies, 260 across the 8 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 10 most frequent:
University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.
University Hospital, Tours has 1 study filed under Pneumonia, Pneumocystis — fewer than ten, so there is no comparison to draw.
3 of the studies in Pneumonia, Pneumocystis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06892951University Hospital, ToursCaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia | 2026-12 |
| NCT06431958University Hospital, BrestDroplet Digital PCR and PCR-free BIOSensors for the Detection of Resistance-associated SNPs in Pneumocystis Jirovecii | 2026-12-31 |
| NCT06890078Assistance Publique - Hôpitaux de ParisOptimizing the Diagnosis of Pneumocystis in Immunocompromised Patients | 2027-07-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Pneumonia, Pneumocystis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the efficacy of administrating daily caspofungin aerosols versus placebo for seven days, in adjunction of conventional systemic antifungal therapy during curative treatment of Pneumocystis pneumonia, on the clinical outcome at the end of the nebulized therapy, in order to support a "GO / NO GO" decision towards a phase III trial of nebulized caspofungin in those patients.
Pneumocystis jirovecii is an airborne-transmissible fungus which can induce pneumonia with severely impaired lung function, especially in immunocompromised patients. At least 1,000 new cases of Pneumocystis pneumonia occur each year in France with approximately 50% of cases suffering from hypoxemia. Around 15% HIV+ and 50% HIV- subjects require mechanical ventilation, and mean duration of hospitalization is about 30 days. Average mortality rate is ≈20% at 3 months, higher for critically ill patients (30%-60%).
To date, cotrimoxazole represents the gold standard anti-Pneumocystis treatment commonly associated with systemic corticosteroids in case of moderate-to-severe infection. However, treatment is long (several weeks) to achieve clearance of the fungus, which might favor lung sequelae like persistent inflammation or post-infectious fibrosis. Furthermore, therapeutic failures have been reported as high as 9-44% of patients. Five other drugs have been commonly used as curative alternatives to cotrimoxazole against P. jirovecii: pentamidine, primaquine + clindamycin, dapsone and atovaquone. Some are responsible for serious side effects, while others are complex to administer or less efficient. All exhibit clinically important drug-drug interactions. Therefore, in such a context, it is important to test new drugs and/or alternative delivery routes for existing therapies.
Echinocandin drugs, including caspofungin, are usually administered daily to treat invasive candidiasis and aspergillosis. They target the fungal cell wall, thus inhibiting the β-(1,3)-D glucan synthase enzyme. Intravenous (IV) echinocandins are generally well tolerated and are not responsibles for major drug-drug interactions. IV caspofungin was also proven effective in animal models of Pneumocystis infection and significantly improve the overall survival. Two human studies showed that in-hospital and 3-month mortality rates were similar between patients receiving daily IV echinocandin and those receiving co-trimoxazole alone. Several case reports also showed 47 successful outcomes with IV caspofungin, alone or in combination with standard treatment. A recent study reported better response and lower in-hospital mortality in patients receiving the combination of cotrimoxazole + IV caspofungin with no severe adverse events. Therefore, IV echinocandins are now recommended in the European therapeutic guidelines for non-HIV patients as a salvage therapy (CII-grade) in association with co-trimoxazole.
However, high molecular weight and elevated protein binding hamper optimal diffusion of IV caspofungin towards the lung alveoli (\<5% plasma concentration), where P. jirovecii thrives. Administration through an aerosol directly delivered into the lung may circumvent this limitation. Technical feasibility of echinocandin nebulization was demonstrated in vitro with several commercial nebulizers that provided aerosol particles with adequat size and pH to ensure lung tolerance. In vivo, nebulized caspofungin, at a dosage equivalent to the usual IV dosage, showed an excellent safety profile in rats. It also reduced the fungal burden by -99% and induced elevated and prolonged concentrations of the drug in the lungs (almost 50% of the total amounts of caspofungin initially deposited into the lungs of infected rats were still detectable at 48 hours) - largely above the usual minimal inhibitory concentrations of fungal pathogens -, while caspofungin detection was almost null in other organs and blood.
Therefore, we hypothesize herein the therapeutic interest of caspofungin aerosols in adjunction with conventional antifungal therapy, as first-line curative treatment, to enhance the clinical recovery and to reduce the morbidity due to Pneumocystis pneumonia. As no clinical trials have been worldwide initiated, human efficacy and safety data of nebulized caspofungin are still lacking and will be first investigated in this study in patients. Thus organized in two successive parts, this phase I/II clinical trial represents a mandatory prelude for this original administration modality of caspofungin.
Inclusion criteria:
Medical management of Pneumocystis pneumonia based on :
Non-inclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Conventional systemic antifungal treatment (systemic co-trimoxazole or systemic second line anti-Pneumocystis salvage therapy) + aerosols of echinocandin (50 mg caspofungin) during one to seven days (according to the regimen retained from the results of part 1 from day-1 to d-7) using vibrating mesh nebulization device
Drug: Caspofungin Acetate 50 MG
Control group: (in part 2 only) Conventional systemic antifungal treatment (systemic co-trimoxazole or systemic second-line anti-Pneumocystis salvage therapy) + aerosols of placebo (0.9% saline in a volume equivalent to the experimental group) during one to seven days (according to the regimen retained from part 1 results) using vibrating mesh nebulization device
Drug: Physiologic saline
open-label non-randomized group, with ascending scheme regarding the dose and rhythm of administration over one week, depending on the tolerance, and closely monitored in ICU to ensure that caspofungin is well tolerated via the inhaled route, and to provide data supporting the proposed administration scheme for part 2. * the first two patients (included one by one) will receive two aerosols (5 mg) during the first week, four days apart on d-1 and d-5 (level 1); * the third and fourth will receive two aerosols (15 mg) during the first week, four days apart on d-1 and d-5 (level 2); * the fifth and sixth will receive two aerosols (50 mg) during the first week, four days apart on d-1 and d-5 (level 3); * the seventh and eighth patients will receive four aerosols (50 mg) two days apart during one week, at d-1, then d-3, d-5 and d-7 (level 4); * the last two patients will have daily aerosols during the first week, from d-1 to d-7 (level 5)
Drug: Caspofungin Acetate 50 MG
The experimental treatment will be administered once daily for up to seven days, through the nebulization route by the means of a disposable vibrating mesh Aeroneb solo® nebulizer with the valved mask (Galway, Ireland). Before generating aerosol, resuspension of the caspofungin powder will be carried out in the same manner than for the IV route, into 10.5 mL saline serum. Preparation of the experimental drug (re-suspension) will be unblindly carried out in a distinct medical office by a nurse neither involved in the healthcare of the included patients, nor in the other parts of the study, data recording or outcome assessment. Once reconstituted, the suspension is expected to be limpid, with neither odour nor foam. Thereafter, its administration will be blindly completed by the clinical staff in charge of the enrolled patient.
Procedures will be exactly the same than those described above for the experimental group, but caspofungin will be replaced during the seven days of intervention by 10mL of 0.9% saline nebulized in the control group for a 15 minute-long process of nebulization (from d-1 to d-7).
Part 1: safety of inhaled caspofungin
* frequency of adverse events * severity of adverse events
Time frame: D-7 (day-7)
Part 2: proportion of patients alive and with a favorable clinical course* at the seventh day (day-7) after the first administration.
Composite outcome defined by at least one of the two following items persisting ≥24 hours in alive patients: * Relative reduction (de-escalation or withdrawal) of respiratory assistance due to clinical improvement (depending on the initial support): * extubation, or * weaning of non-invasive ventilatory support, or * weaning of nasal high-flow or low-flow oxygen therapy; (NB: all participating centers will implement uniform protocols for ventilatory assistance weaning) * Occurrence of a +50% increase in oxygenation (PaO2 / FiO2 ratio vs. the worst value observed after inclusion).
Time frame: D7 (day-7)
Individual components of the composite primary outcome at day-7 (d-7)
* All-cause mortality and Pneumocystis pneumonia-related mortality * Improvement of respiratory function: * Proportion of patients alive and with relative reduction (de-escalation or withdrawal) of respiratory assistance (in percentage) * Proportion of patients alive and with a +50% increase in oxygenation (PaO2 / FiO2 ratio vs. the worst value observed after inclusion) (in percentage)
Time frame: D7 (day-7)
Safety of nebulized caspofungin in patients with Pneumocystis pneumonia through
* Occurrence of serious and non-serious pulmonary adverse events and adverse effects at day-1 (d-1), d-2, d-3, d-4, d-5, d-6, and d-7 (with active monitoring of the nebulization procedure), and serious pulmonary adverse events and adverse effects at hospital discharge, d-28 and d-90 * Occurrence of other serious adverse events and adverse effects at day-1 (d-1), d-2, d-3, d-4, d-5, d-6, d-7, hospital discharge, d-28 and d-90 * Liver and kidney markers at day 1 (d-1), d-3, d-7, d-28 and d-90 * transaminases (in international units/liter) * glutamate transferase (in international units/liter) * alkaline phosphatase (in international units/liter) * serum creatinine (in micromol/liter) * urea (in millimol/liter) * Blood counts (same dates) * complete blood count (in giga/liter) * platelets (in giga/liter) * Serum electrolytes (same dates) * sodium (in mmol/liter) * potassium (in mmol/liter) * chloride (in mmol/liter) * bicarbonates (in mmol/liter)
Time frame: day-1 (d-1), d-2, d-3, d-4, d-5, d-6, and d-7
Pharmacokinetics of nebulized caspofungin
in blood at 0, 2, 4, 6, 12, 24 hours, plus residual concentration at day-3 (d-3) and d-7 for the five first included patients receiving caspofungin, and in tracheo-bronchial aspirates at 4, 6, 24 h, at day-3 (d-3) and d-7 (or just before extubation if still alive at time of extubation) for the five first included patients receiving caspofungin and who are intubated. Caspofungin concentration measurements (in milligram/liter) will be centrally carried out at Tours university hospital at the end of the study only for patients who received nebulized caspofungin (intervention group), once the blind process will be lifted).
Time frame: 0, 2, 4, 6, 12, 24 hours, plus residual concentration at day (d-3) and d-7
Mortality
* All-cause at hospital discharge, day-28 (d-28) and d-90 * Pneumocystis pneumonia-related at hospital discharge, day-28 (d-28) and d-90
Time frame: day-28 (d-28) and d-90
Morbidity
* Number of days alive without any ventilatory / oxygen support * Duration to clinical stability (from inclusion to hospital discharge: * maximum daily temperature ≤ 37.8 °C * maximum daily heart pace ≤ 100 bpm * maximum daily respiratory pace ≤ 24 cpm * minimum daily systolic blood pressure ≥ 90 mmHg * arterial oxygenation saturation ≥ 90% or PaO2 ≥ 60 mmHg while breathing room air, or PaO2/FiO2 ratio ≥ 285 mmHg, without an increase in the intensity of the ventilatory support * normal mental status * Duration of invasive ventilatory support * Duration of invasive and non-invasive ventilatory support * Duration to clinical healing : * clinical stability (cf. above) * 24h weaning of mechanical respiratory support due to patient's clinical improvement * Duration of hospital stay (in days) * Duration of ICU stay (in days) * Change in the sepsis-related organ failure assessments (SOFA) score * Requirement of a second-line (salvage) anti-Pneumocystis curative therapy (yes or no)
Time frame: day-1 (d-1), d-7 and d-21
Pulmonary and systemic markers of lung infection (to assess the fungal clearance)
* Evolution of hypoxemia: • alveolar-to-arterial oxygen gradient, ratio of arterial partial pressure in oxygen and pulsed oxymetry to fraction of inspired oxygen (in millimeter Hg) * LDH enzyme in blood (in international units/liter) * BDG fungal antigen in blood (in pigogram / milliliter) * RT-qPCR for P jirovecii nucleic acids in blood and in tracheal aspirates (in number of amplification cycles) * Impact on the micro-organism diversity in respiratory airways and infections * monitoring the expression of specific genes for distinguishing the relative representativeness between P. jirovecii asci and trophic forms from trachea-bronchial aspirates * identification and counting of fungal colonies from trachea-bronchial aspirates (in number of colony-forming units (CFU)) * identification and counting of bacterial colonies from trachea-bronchial aspirates (in CFU) * Genotyping of P. jirovecii strains based on microsatellites markers and sequencing of DHPS/DHFR genes in respiratory fluids
Time frame: day-1 (d-1), d-3, d-7, d-28 and d-90
Plan to share: Yes — All research data can be requested
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: At the end of the study (2028)
Access criteria: Upon request
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Jun 2025 → Dec 2025 and primary completion Jun 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Caspofungin